Safety, Pharmacokinetics, and Immunogenicity of Astegolimab, an Anti‐ST2 Monoclonal Antibody, in Randomized, Phase I Clinical Studies

ABSTRACT Astegolimab, a fully human immunoglobulin G2 monoclonal antibody, binds with high affinity to ST2, the interleukin‐33 receptor, thereby blocking ST2/interleukin‐33 binding and subsequent inflammatory cascades involved in inflammatory diseases. Here, we present three randomized, double‐blind...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Wenhui Zhang, Dorothy Cheung, Alice Fong, Logan Brooks, Michele A. Grimbaldeston, Audrey Arjomandi, Xiaoying Yang, Ajit Dash, Hansen Wong, Jane R. Parnes, Divya Mohan
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Wiley 2025-10-01
Edice:	Clinical and Translational Science
Témata:	monoclonal antibodies pharmacokinetics phase 1 safety
On-line přístup:	https://doi.org/10.1111/cts.70338
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!